Organization
Sun Pharmaceutical Industries
23 clinical trials
Clinical trial
Post-authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With TildrakizumabStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Effect of Cequa™ in Subjects With Dry Eye Disease That Is Currently Inadequately Controlled While on Cyclosporine 0.05% Ophthalmic EmulsionStatus: Completed, Estimated PCD: 2022-06-24
Clinical trial
A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.Status: Completed, Estimated PCD: 2023-09-18
Clinical trial
The Combination Use of Winlevi and Adapalene 0.3% Gel in Real Life Acne TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Therapeutic Equivalence Study of Generic Brinzolamide 1% Ophthalmic Suspension Compared to Reference Listed Drug Azopt® (Brinzolamide) Ophthalmic Suspension 1% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.Status: Completed, Estimated PCD: 2022-12-29
Clinical trial
Combination Treatment of Winlevi With Duac Gel in Patients With Acne VulgarisStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque PsoriasisStatus: Recruiting, Estimated PCD: 2031-05-23
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque PsoriasisStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic DermatitisStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee OsteoarthritisStatus: Completed, Estimated PCD: 2022-05-04
Clinical trial
A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental VitiligoStatus: Completed, Estimated PCD: 2022-05-20
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic ArthritisStatus: Completed, Estimated PCD: 2019-03-01
Clinical trial
An Open-Label, Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Moderate to Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2021-11-02
Clinical trial
A Non-interventional, Multi-national, Multi-center Post-authorization Safety Study (PASS) to Assess the Long Term Safety and Tolerability of Odomzo (Sonidegib) Administered in Patients With Locally Advanced Cell Carcinoma (laBCC)Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the ScalpStatus: Completed, Estimated PCD: 2022-02-17
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail PsoriasisStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Clinical Evaluation of the Sebum Reduction Induced by Clascoterone Cream 1%Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Clinical Study to Assess the Barrier Impact of WinleviStatus: Completed, Estimated PCD: 2023-12-16
Clinical trial
The Efficacy and Safety of Winlevi in Skin of Color Patients With AcneStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Histologic and LCMS Evaluation of the Sebaceous Gland Changes Induced by Clascoterone Cream 1%Status: Not yet recruiting, Estimated PCD: 2024-09-01